Neuronetics, Inc.

STIM

US64131A1051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-23 EDT			5-day change	1st Jan Change
2.3 ^USD	-2.54%		-8.73%	-20.69%

05-15	Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents	CI
05-14	William Blair Upgrades Neuronetics to Outperform From Market Perform	MT

Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2024

May 07, 2024 at 07:30 am

Neuronetics, Inc. provided earnings guidance for the second quarter of fiscal year 2024. For the quarter, the company expects total worldwide revenue between $18.0 million and $19.0 million.

Latest news about Neuronetics, Inc.

Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents	05-15	CI
William Blair Upgrades Neuronetics to Outperform From Market Perform	05-14	MT
Transcript : Neuronetics, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Earnings Flash (STIM) NEURONETICS Reports Q1 Revenue $17.4M	05-07	MT
Neuronetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2024	05-07	CI
Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation	04-10	CI
Neuronetics, Inc. Announces John K. Bakewell, Joseph H. Capper and Dr. Wilfred E. Jaeger Not Stand for Reelection to the Board	03-28	CI
Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21	03-25	DJ
Neuronetics Gets US FDA Clearance for Treatment of Adolescents with Depression; Shares Rise	03-25	MT
Neuronetics, Inc. Announces Clearance from the U.S. Food and Drug Administration for NeuroStar Advanced Therapy	03-25	CI
Neuronetics, Inc. Announces 5-Year Exclusive Partnership with Transformations Care Network	03-07	CI
Transcript : Neuronetics, Inc., Q4 2023 Earnings Call, Mar 05, 2024	03-05
Earnings Flash (STIM) NEURONETICS Reports Q4 Revenue $20.3M	03-05	MT
Neuronetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-05	CI
Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	03-05	CI
North American Morning Briefing : S&P 500 Futures -2-	03-05	DJ
Neuronetics Launches Latest Evolution in Its Trakstar® Patient Data Management System	02-12	CI
Top Premarket Gainers	01-25	MT
Neuronetics, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2023	01-08	CI
Neuronetics Receives 510(K) Clearance for Neurosite Coil Placement Accessory	12-18	CI
Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan	12-04	CI
Neuronetics, Inc. Elevates Depression Treatment with Cutting-Edge Technology Advancements	11-13	CI
Transcript : Neuronetics, Inc., Q3 2023 Earnings Call, Nov 07, 2023	11-07
Earnings Flash (STIM) NEURONETICS Reports Q3 Revenue $17.9M	11-07	MT

Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-30 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Neuronetics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.3 USD

Average target price

7 USD

Spread / Average Target

+204.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
NEURONETICS, INC.	-20.69%	68.99M
THERMO FISHER SCIENTIFIC	+10.22%	223B
DANAHER CORPORATION	+12.99%	194B
INTUITIVE SURGICAL, INC.	+18.09%	141B
BOSTON SCIENTIFIC CORPORATION	+28.66%	109B
SIEMENS HEALTHINEERS AG	+2.09%	64.85B
EDWARDS LIFESCIENCES CORPORATION	+14.70%	52.7B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+6.68%	51.77B
AGILENT TECHNOLOGIES, INC.	+8.29%	44.12B
GE HEALTHCARE TECHNOLOGIES INC.	+2.60%	36.21B

Other Advanced Medical Equipment & Technology

Neuronetics, Inc.

Equities

STIM

US64131A1051

Advanced Medical Equipment & Technology

Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2024

Latest news about Neuronetics, Inc.

Chart Neuronetics, Inc.

Company Profile

Income Statement Evolution

Ratings for Neuronetics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology